overview
Systemic nephrogenic fibrosis is a rare disease that occurs primarily in people with advanced kidney disease, with or without dialysis. Systemic nephrogenic fibrosis can resemble skin diseases such as scleroderma and scleromyxedema, with thickening and darkening developing over large areas of the skin.
Systemic nephrogenic fibrosis can also affect internal organs such as the heart, kidneys, and lungs and prevent the muscles and tendons in the joints from shortening (joint contracture). Nephrogenic systemic fibrosis Treatment in Nizamabad
symptoms
ystemic nephrogenic fibrosis can begin days to months after exposure to a contrast agent containing gadolinium. Some signs and symptoms of nephrogenic systemic fibrosis may include:
- Swelling and tightening of the skin
- Thickening and hardening of the skin, usually on the arms and legs and sometimes on the body, but almost never on the face or head
- Skin that may be “woody” and develop an orange peel appearance and darkening (excessive pigmentation)
- Severe burning, itching, or sharp Painless in the affected areas
- Thickening of the skin that inhibits movement and leads to a loss of joint flexibility
- Rarely blisters or ulcers
The reasons
The exact cause of nephrogenic systemic fibrosis is not fully understood. Exposure to gadolinium-containing contrast agents during magnetic resonance imaging (MRI) has been identified as a trigger for the development of this disease. The Food and Drug Administration (FDA) recommends avoiding gadolinium-containing contrast agents in people with acute kidney failure or chronic kidney disease. Nephrogenic systemic fibrosis Treatment in Nizamabad
Other conditions that may lead to or promote disease with severe kidney disease and exposure to a gadolinium-containing contrast agent include the following:
- Using high-dose erythropoietin (EPO), a hormone that promotes red blood cell production and is often used to treat anemia
- Recent vascular surgery
- Blood clotting problems
- Severe infection
Risk factors
The highest risk of nephrogenic systemic fibrosis after exposure to gadolinium is in those who:
- Have moderate to severe kidney disease
- You have had a kidney transplant but your kidney function is impaired
- You will be given hemodialysis or peritoneal dialysis
- You have an acute kidney injury